

Search for cure against the lethal disease ALS boosted by new investor

The ALS Investment Fund announces investment by Rabo Private Equity

Amsterdam, The Netherlands (6 November, 2017) — Today, the ALS Investment Fund announced that it has reached an agreement with Rabo Private Equity, the investment arm of Rabobank, on a capital commitment of just above € 3 million, which will boost the funding for finding a cure against the lethal disease ALS.

The ALS Investment Fund focuses on equity investments in biotech companies that develop therapies against the disease ALS. To date, it has invested in two portfolio companies: Amylyx Inc. (USA) and Orphazyme ApS (Denmark). Both investments are dedicated to a Phase II clinical trial that could lead to a registration of a new therapy.

“We are very excited and proud, having landed our first institutional investor” says **Felix von Coerper**, who heads the fund management team. “Rabo Private Equity complements our existing investor base consisting of family offices and high net worth individuals, all of whom are supporting the social impact we seek to make in the field of ALS, in addition to a financial return. The participation of Rabo Private Equity enables us to scale-up our investments and increase our potential impact. It represents an important contribution to our objective of investing approx. € 30 million in 8 companies over the coming 3 years”.

The investment comes from Rabo Private Equity, the investment arm of Rabobank. Rabobank’s leadership is dedicated in supporting the search for a cure against the lethal disease ALS in particular.

Jan van Nieuwenhuizen, executive board member of Rabobank Group, comments: “In the Netherlands, the level of ALS-related knowledge and care is advanced, compared to other countries in Europe. This is due to the important work of Dutch foundations, patient organizations, social workers and top-class scientists and clinicians at the University Medical Center Utrecht and Academic Medical Center Amsterdam. We are very pleased that we can contribute to a global initiative coming from The Netherlands”.

About the ALS Investment Fund

The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. The ALS Investment Fund was initiated by Dutch ALS patients and is advised by a top-tier European VC firm, Life Sciences Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a deep network in the space. More information is available at <http://www.alsinvestmentfund.com/>.

About Rabo Private Equity

Rabo Private Equity is the captive alternative investment arm of Rabobank investing in private equity and venture capital opportunities. Its mission is to pursue investments that are aligned with the “Banking for the Netherlands and the global Banking for Food” strategy of Rabobank thereby supporting eligible companies that are core to this strategy with equity. In the Netherlands Rabo Private Equity invests directly and indirectly in operational companies and focuses on young, entrepreneurial companies to mature and growing companies in need

of equity to realize their ambitions with the support of equity and reliable investor partners. Internationally Rabo Private Equity invests in F&A focused funds driving value across the entire F&A value chain.

<http://www.raboprivateequity.nl/>

About Rabobank Group

Rabobank is an international financial services provider operating on the basis of cooperative principles. It offers retail banking, wholesale banking, private banking, leasing and real estate services. As a cooperative bank, Rabobank puts customers' interests first in its services.

Rabobank is committed to being a leading customer-focused cooperative bank in the Netherlands and a leading food and agri bank worldwide. Rabobank employs approximately internal and external 44,600 people. Rabobank Group is active in 40 countries.

For more information about the Rabobank Group go to www.rabobank.com.

For more information about Rabobank

Press office, Madelon Kaspers, Madelon.Kaspers@Rabobank.nl, Tel +31 610887244

Contact:

SUNU Ventures BV

Johannes Vermeerplein 9

1071 DV Amsterdam

The Netherlands

contact@alsinvestmentfund.com